APCS and idiopathic pulmonary fibrosis: Recent studies have reported that a recombinant human pentraxin 2, named PRM-151, is well tolerated and slows the decline of lung function in IPF patients, suggesting that modulation of macrophages differentiation and activation may serve as potential therapies for treating lung fibrosis in the future [167,168].